In-person presentation on Monday, June 13th at 1:45 PM PT
CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will present on Monday, June 13, 2022 at 1:45 PM PT at the 2022 BIO International Convention being held in San Diego, CA.
In addition to the presentation, management will be available to participate in one-on-one meetings with industry executives and qualified members of the investor community who are registered to attend the conference. To schedule a meeting with the Company, please reach out through the BIO partnering system.
For more information, please visit the conference website.
About BIO BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information, please visit www.bio.org.
About Palisade Bio Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aim to aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset LB1148, advancing toward Phase 3, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in the return of bowel function and a decrease in the length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with the chronic disruption to the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.
Palisade Bio Investor Relations Contact: Dawn Hofmeister ir@palisadebio.com
Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com
A Food and Drug Administration advisory committee on Thursday voted 15-0 that the benefits of Bluebird Bio Inc.'s experimental gene therapy outweigh the risks for patients younger than 18 years old who are being treated for early cerebral adrenoleukodystrophy. Bluebird's stock was halted on Thursday while the committee discussed and then voted on elivaldogene autotemcel. In a news release, the company said that if the therapy receives FDA approval, it "will be the first and only gene therapy for
Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.
The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.
GSK plc (NYSE: GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. An Independent Data Monitoring Committee reviewed the interim analysis, and the primary endpoint was exc
A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to a more holistic approach to obesity treatment. A potential multibillion-dollar market beckons them.
After securing a place in a European program designed to accelerate the process of getting medicines to patients, BioCryst Pharmaceuticals has landed a spot in a similar U.S. program.
Tuesday was a crucial day for Novavax (NASDAQ: NVAX). At long last, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) met to review the company's COVID-19 vaccine data. A negative recommendation from the FDA advisory committee held the potential to deliver a crushing blow.
Dramatic levels of weight loss are being attained in clinical trials of drugs originally developed for diabetes.
An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. After yo-yoing Wednesday, NVAX stock settled up.
It’s been a good week for Novavax. The Gaithersburg biotech is now a step away from potentially getting its first product to market, after the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee gave its nod to Novavax’s experimental Covid-19 vaccine at its meeting Tuesday. The FDA, which typically listens to the advisory committee’s recommendations, must now decide whether to greenlight the protein-based shot for emergency use authorization for adults in the U.S. The Centers for Disease Control and Prevention would then have to endorse its use.
(Reuters) -The U.S. government expects to receive an additional 300,000 doses of Bavarian Nordic's Jynneos vaccine against monkeypox in the next few weeks as cases across the country jumped to 45 from 25 four days ago. The United States currently holds about 72,000 doses of Jynneos in its strategic national stockpile, Dawn O'Connell, assistant secretary for preparedness and response at the U.S. Department of Health and Human Services told reporters at a news briefing. Earlier on Friday, the United States placed an order for an additional 500,000 doses of bulk vaccine to be delivered later this year.
Early results from a late-stage study in a rare blood disorder showed that patients given a placebo at some clinical trial sites in Eastern Europe performed better than those on drug.
Participants in small experimental cancer drug trial see tumors vanish
By John Vandermosten, CFA NASDAQ:TLSA Clinical Results for Second SPMS Patient Tiziana Life Sciences PLC (NASDAQ:TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8 th press release. The ~40 year old individual that was enrolled as the second patient in the trial exhibited clinical improvements on several measures, including
The more than 24,000 comments that rolled into the Federal Trade Commission have sparked a deep probe of pharmacy benefit managers by the agency.
Here’s what experts say about the future of diversification.
Mission Produce reported a revenue increase, boosted by higher prices, for the fiscal second quarter despite inflation that has reached a 40-year high
Jim Cramer says he doesn't see the economy falling into stagflation. He thinks we just got overheated coming out of the pandemic and now need time to cool off.
SANTA ROSA, Calif., June 9, 2022 /3BL Media/ - Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that delivers advanced design and validation solutions to help accelerate innov...
A cooler inflation figure would provide some reassurance to those hoping decades-high inflation had peaked in March.